Literature DB >> 10678620

B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia.

Y Kaneko1, K Kuwano, R Kunitake, M Kawasaki, N Hagimoto, N Hara.   

Abstract

Interstitial lung diseases are thought to be associated with the infiltration of activated T-lymphocytes. To induce an effective immune response, antigen-presenting cells have to not only present antigenic peptide with major histocompatibility complex (MHC) molecules to T-lymphocytes but also express B7 molecules. Therefore, the expression of B7-1, B7-2 and class II MHC molecules was investigated in lung tissues from patients with idiopathic pulmonary fibrosis (IPF) and bronchiolitis obliterans-organizing pneumonia (BOOP), and in normal lung parenchyma as a control, using immunohistochemical localization. B7-1 and B7-2 were aberrantly expressed in bronchiolar and alveolar epithelial cells, and class II MHC molecules were also aberrantly expressed in bronchiolar epithelial cells in IPF. B7-1 was aberrantly expressed in bronchiolar epithelial cells in BOOP. There was no significant difference in the expression of these proteins in alveolar macrophages between IPF and control subjects. However, B7-2 and class II MHC molecule expression in alveolar macrophages was decreased in BOOP compared with that in control subjects. Expression of CD28 and CTLA4, receptors for B7 molecules, was detected in infiltrating lymphocytes in lung tissues in IPF and BOOP. It was concluded that bronchiolar and alveolar epithelial cells may actively participate in the pathophysiology of idiopathic pulmonary fibrosis through the aberrant expression of B7 and class II major histocompatibility complex molecules. The dysregulation of these molecules in epithelial cells may lead to the activation of autoreactive T-lymphocytes, which might contribute to the pathogenesis of fibrosing lung diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678620

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Expression of major histocompatibility complex class II and CD80 by gingival epithelial cells induces activation of CD4+ T cells in response to bacterial challenge.

Authors:  Takashi Matsuyama; Toshihisa Kawai; Yuichi Izumi; Martin A Taubman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions.

Authors:  C K Haston; T G Tomko; N Godin; L Kerckhoff; M T Hallett
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

3.  Extracellular Vesicle Surface Signatures in IPF Patients: A Multiplex Bead-Based Flow Cytometry Approach.

Authors:  Miriana d'Alessandro; Piera Soccio; Laura Bergantini; Paolo Cameli; Giulia Scioscia; Maria Pia Foschino Barbaro; Donato Lacedonia; Elena Bargagli
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

Review 4.  Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts.

Authors:  Jonathan E Wosen; Dhriti Mukhopadhyay; Claudia Macaubas; Elizabeth D Mellins
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

Review 5.  Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?

Authors:  JanWillem Duitman; Tom van den Ende; C Arnold Spek
Journal:  J Clin Med       Date:  2019-09-26       Impact factor: 4.241

6.  SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator.

Authors:  Lisiena Hysenaj; Samantha Little; Kayla Kulhanek; Oghenekevwe M Gbenedio; Lauren Rodriguez; Alan Shen; Jean-Christophe Lone; Leonard C Lupin-Jimenez; Luke R Bonser; Nina K Serwas; Kriti Bahl; Eran Mick; Jack Z Li; Vivianne W Ding; Shotaro Matsumoto; Mazharul Maishan; Camille Simoneau; Gabriela Fragiadakis; David M Jablons; Charles R Langelier; Michael Matthay; Melanie Ott; Matthew Krummel; Alexis J Combes; Anita Sil; David J Erle; Johannes R Kratz; Jeroen P Roose
Journal:  bioRxiv       Date:  2021-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.